Adam D Cohen, MD

Myeloma
Amyloidosis
Immunotherapy

[Adam D Cohen, MD @CohenAd_MMdoc]

@SandyWong02111 @brendanweiss anyone know if the European VMD vs. MD trial stratified by cytogenetics? #amyloidosisjc

[Adam D Cohen, MD @CohenAd_MMdoc]

Intriguing data but small numbers overall. Mayo group couldn't confirm findings in their series. https://t.co/5vHNt5InZH #amyloidosisjc

[Adam D Cohen, MD @CohenAd_MMdoc]

Hi everyone. About 60% had t(11;14). is this representative of what you are generally finding in your practices? #amyloidosisJC

[Adam D Cohen, MD @CohenAd_MMdoc]

Royal pumpkins @woodloch

[Adam D Cohen, MD @CohenAd_MMdoc]

@brendanweiss @PennCancer - typo alert: Carfilzomib MTD actually 20/36 in rel/ref AL. #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

Thanks everyone!! #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@myelomacinderel @mtmdphd Depends on target, but haven't seen increased infections with chkpt inhibitors or Elo #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@NorthTxMSG agreed. may need combinations of approaches - mAbs, vaccines, cellular therapy to eradicate disease #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@mtmdphd yes multiple vaccine targets in development - idiotype, MAGE-A3, CS1, XBP1. Also dendritic cell-myeloma cell fusions. #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

#mmsm T4 Active vaccination aims to induce patient’s own immune system to attack myeloma cells

[Adam D Cohen, MD @CohenAd_MMdoc]

@MyelomaTeacher yes, that's been seen with ckpt inhibitors in other cancers. usually controllable. #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

May be beneficial to combine CAR T cells with autoSCT http://t.co/5NPTNEToTV #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@MyelomaTeacher That's the hope but too early to know if will work in myeloma and for how long. #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

#mmsm Multiple CAR targets in MM: CD19, CD38, CS1, BCMA, CD138, kappa. Recent review http://t.co/PQAq6QKTuM

[Adam D Cohen, MD @CohenAd_MMdoc]

@MyelomaTeacher yes, takes patient's own T cells, adds receptor to target MM cell, then infuses back to patient. http://t.co/0cVTp8ub8K

[Adam D Cohen, MD @CohenAd_MMdoc]

@mtmdphd Makes sense, since relatively low toxicity. Currently being tested in trials. #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@myelomacinderel that's the idea that you may get better memory immune response, but not proven yet in humans #mmsm

[Adam D Cohen, MD @CohenAd_MMdoc]

@MyelomaTeacher #mmsm ckpt inhibitor here means removing a brake on the immune system. Yes, mAb target receptors on outside of cell

[Adam D Cohen, MD @CohenAd_MMdoc]

#mmsm Urelumab: Anti-CD137 agonist Ab – provides costimulatory signal to enhance T and NK cell proliferation, persistence, function

[Adam D Cohen, MD @CohenAd_MMdoc]

#mmsm Nivolumab (antiPD1) with no single-agent responses but prolonged SD in subset of rel/ref MM http://t.co/vknllaCHt7